{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:08:09Z","timestamp":1784372889112,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ygyno.2017.02.032","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T02:02:00Z","timestamp":1489456920000},"page":"346-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-0682","authenticated-orcid":false,"given":"Jacob","family":"McGee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasily","family":"Giannakeas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-2933","authenticated-orcid":false,"given":"Beth","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lubinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Gronwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Risch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Neuhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Kotsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5798-0626","authenticated-orcid":false,"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ygyno.2017.02.032_bb0005","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"12","key":"10.1016\/j.ygyno.2017.02.032_bb0010","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nrclinonc.2010.166","article-title":"BRCA mutations in the management of breast cancer: the state of the art","volume":"7","author":"Narod","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.032_bb0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.ygyno.2017.02.032_bb0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ijc.26369","article-title":"The risk of breast cancer in women with a BRCA1 mutation from North America and Poland","volume":"131","author":"Lubinski","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2017.02.032_bb0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2015.11.009","article-title":"Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status","volume":"140","author":"Kotsopoulos","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.02.032_bb0030","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ygyno.2015.06.016","article-title":"Why have ovarian cancer mortality rates declined? Part II. Case-fatality","volume":"138","author":"Sopik","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2017.02.032_bb0035","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","article-title":"Can advanced-stage ovarian cancer be cured?","volume":"13","author":"Narod","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.02.032_bb0040","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jnci\/djs494","article-title":"Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2","volume":"105","author":"McLaughlin","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.ygyno.2017.02.032_bb0045","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ijc.29386","article-title":"Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers","volume":"137","author":"Kotsopoulos","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"26","key":"10.1016\/j.ygyno.2017.02.032_bb0050","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2012.45.3571","article-title":"Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer","volume":"31","author":"Huzarski","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.032_bb0055","author":"Statistics Canada"},{"key":"10.1016\/j.ygyno.2017.02.032_bb0060","unstructured":"International Agency for Research on Cancer. Cancer. Globocan 2012: Estimated Cancer Incidence, Mortality and and Prevalence Worldwide, 2012 2012. Available from: http:\/\/globocan.iarc.fr\/Pages\/age-specific_table_sel.aspx."},{"issue":"5","key":"10.1016\/j.ygyno.2017.02.032_bb0065","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cncr.27839","article-title":"The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1\/BRCA2 mutation carriers: implications for counseling","volume":"119","author":"Vencken","year":"2013","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2017.02.032_bb0070","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cncr.27842","article-title":"Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer","volume":"119","author":"Domchek","year":"2013","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.ygyno.2017.02.032_bb0075","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817301531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817301531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T11:26:31Z","timestamp":1535973991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817301531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0090825817301531"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.032","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}